[Immunologic correction using thymus gland preparation (T-activin) in the programmed treatment of patients with non-lymphoid leukemia].
Data have been presented on the observation of 80 children with acute myeloid leukemia, among them 26 patients who, in addition to chemotherapy, were given tactivin treatment. The authors have proved the necessity of long-term tactivin administration in acute myeloid leukemia (no less than 2-3 years). that permits not only reducing the incidence of intercurrent diseases, but also increasing the duration of the remission period.
Drozdova
T S
TS
Makhonova
L A
LA
Maiakova
S A
SA
Tabagari
D Z
DZ
D000276:Adjuvants, Immunologic; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000276:immunology; D008231:Lymphopenia / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D010455:Peptides / Q000627:therapeutic use*; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology*; D013949:Thymus Extracts / Q000627:therapeutic use*
D000276:Adjuvants, Immunologic; D010455:Peptides; D013949:Thymus Extracts; C036191:T-activin
Immunokorrektsiia preparatom timusa (T-aktivinom) v programmnom lechenii deteĭ, bol'nykh s ostrym nelimfoidnym leĭkozom.